Advertisement

Endoscopic Bariatric Therapies

  • Anthony Choi
  • Reem Sharaiha
Chapter

Abstract

Obesity has traditionally been treated with lifestyle modification, diet, pharmacologic agents, and more recently bariatric surgeries. Endoscopic bariatric therapies (EBTs) are emerging as a novel approach that is minimally invasive yet efficacious and safe. The goal of EBTs may be for primary, preemptive, bridge, or metabolic therapy, which are classified according to the primary location of the intervention (e.g., gastric vs small bowel) as well as the type of procedure. In this chapter, the authors review the diverse techniques and technologies involved in EBTs, the data behind each, as well as the future implications in the field of obesity treatment.

Keywords

Obesity Endoscopy Bariatrics Endoscopic bariatric therapy Gastroplasty Balloon Sleeve Mucosal resurfacing 

References

  1. 1.
    Bazerbachi F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic bariatric therapies as an obesity intervention. Clin Endosc. 2017;50(1):42–50.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes. 2017;41(3):427–33.CrossRefGoogle Scholar
  3. 3.
    ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.e5.CrossRefGoogle Scholar
  4. 4.
    Sullivan S, Swain JM, Woodman G, et al. 812d The Obalon Swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6- month randomized sham controlled trial. Gastroenterology. 2016;150(4):S1267.CrossRefGoogle Scholar
  5. 5.
    Brooks J, Srivastava ED, Mathus-Vliegen EMH. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24(5):813–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Abu Dayyeh BK, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology. 2017;152(4):716–29.CrossRefPubMedGoogle Scholar
  7. 7.
    Marinos G, Eliades C, Raman Muthusamy V, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve Gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017;15(1):37–43.e1.CrossRefPubMedGoogle Scholar
  9. 9.
    Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013;78(3):530–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015;47(2):164–6.PubMedGoogle Scholar
  11. 11.
    Lopez-Nava G, Galvão MP, da Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy. 2015;47(5):449–52.PubMedGoogle Scholar
  12. 12.
    Galvão-Neto MDP, Grecco E, de Souza TF, de Quadros LG, Silva LB, Campos JM. Endoscopic sleeve gastroplasty – minimally invasive therapy for primary obesity treatment. Arq Bras Cir Dig. 2016;29(Suppl 1(Suppl 1)):95–7.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017;27(10):2649–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Sharaiha RZ, Kumta NA, Saumoy M, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017;15(4):504–10.CrossRefPubMedGoogle Scholar
  15. 15.
    Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose (SM) vs medical therapy. Obes Surg. 2017;27(2):310–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Sullivan S, Swain JM, Woodman G, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301.CrossRefGoogle Scholar
  17. 17.
    Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145(6):1245–52.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Forssell H, Norén E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy. 2015;47(1):68–71.PubMedGoogle Scholar
  19. 19.
    Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57.CrossRefPubMedGoogle Scholar
  20. 20.
    Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31(Suppl 2):S290–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Klein S, Fabbrini E, Patterson BW, et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity (Silver Spring). 2012;20(6):1266–72.CrossRefGoogle Scholar
  22. 22.
    Rhee NA, Vilsbøll T, Knop FK. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. Diabetes Obes Metab. 2012;14(4):291–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Vilarrasa N, de Gordejuela AGR, Casajoana A, et al. Endobarrier® in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2017;27(3):569–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia. 2009;52(11):2270–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Quezada N, Muñoz R, Morelli C, et al. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Surg Endosc. 2018;32(1):260–7.Google Scholar
  26. 26.
    Jirapinyo P, Haas AV, Thompson CC. 549 effect of the Duodenal-Jejunal bypass liner on glycemic control in type-2 diabetic patients with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Gastrointest Endosc. 2017;85(5):AB82–3.Google Scholar
  27. 27.
    Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017;152(7):1791–801.CrossRefPubMedGoogle Scholar
  28. 28.
    Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc. 2011;25(9):3028–33.CrossRefPubMedGoogle Scholar
  29. 29.
    Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29(11):3298–303.CrossRefPubMedGoogle Scholar
  30. 30.
    Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in subjects with obesity and diabetes. Gastrointest Endosc. 2017;86:904–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyNew York Presbyterian-Weill Cornell Medical CenterNew YorkUSA

Personalised recommendations